A carregar...
Publicação
Effect of funding medications for nicotine dependence on tobacco control
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 518.72 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Pharmacological treatments for smoking associated with psychological counseling triple the chances of quitting. However, the accessibility of these drugs is limited by their financial cost. With this review we aim to demonstrate the effect of partial or full funding in terms of efficacy, effectiveness, cost-effectiveness and quality of life. We conducted a literature search for articles related to the issues mentioned above: analysis of the efficacy, effectiveness and cost-effectiveness of pharmacological treatments for nicotine dependence and the effect of their funding. It is shown that the funding of pharmacological treatment can increase the efficacy and effectiveness of smoking cessation interventions. Such funding increases motivation to make a quit attempt. In addition, these strategies can increase self-efficacy, generate social influence and change attitudes toward quitting. Although the funding of pharmacological treatment benefits all smokers, there are certain populations of smokers who are more sensitive to funding strategies such as social groups with lower incomes and lower educational attainment. These funding strategies for smoking cessation interventions have been shown to improve the health and quality of life of the population, as well as the economy, while reducing tobacco use.
Descrição
Funding Information: Smoking at the time of surgery is associated with postoperative complications. Quitting smoking before surgery is linked to fewer complications during the hospital stay. A Spanish study analyzed whether a smoking cessation intervention before surgery is economically worthwhile when funded by the National Health System. Smoking cessation increased by 21.7% with funding; the rate was 32.5% when funded versus10.7% without funding, producing 9611 extra quitters. The cost per averted smoker was \u20AC1753 with a benefit of \u20AC503, achieving a net economic benefit of \u20AC4.8 million per year. The return on investment was 28.7% annually, equivalent to \u20AC1.29 per \u20AC1 of investment. 43 Publisher Copyright: © 2025 Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Palavras-chave
Efficacy Financing Pharmacological treatment Smoking Pulmonary and Respiratory Medicine SDG 3 - Good Health and Well-being